Birgit Markefski-Gaschler
Biberach An Der Riss, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study.
Journal: OncoTargets and therapy
Published: August 21, 2018
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Journal: Oncology research and treatment
Published: February 07, 2017
Embracing model-based designs for dose-finding trials.
Journal: British journal of cancer
Published: January 24, 2017
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.
Journal: ESMO open
Published: September 08, 2016
Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 12, 2016
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 11, 2016
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 03, 2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Journal: The Lancet. Oncology
Published: January 14, 2014
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Journal: Clinical lung cancer
Published: January 24, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026